In the October 19 Biotechnology Report, Biotech industry expert Maged Shenouda discusses the outlook for the sector and for investors. Mr. Shenouda is an Executive Director in the health care group of UBS Investment Research, specializing in coverage of large-cap biotechnology companies. An Analyst since 1999, he joined UBS in 2004 from J.P. Morgan, where he had served as a Biotechnology Analyst since 2000. Mr. Shenouda earlier worked as biotech and European Pharmaceuticals Analyst at Bear, Stearns & Co., and as an Associate Pharmaceuticals Analyst at Solomon Smith Barney. Prior to that, he was a Management Consultant with Price Waterhouse, focusing on the pharmaceutical industry, and he served as a Pharmaceutical Sales Representative for Abbott Laboratories. Mr. Shenouda holds an MBA in marketing from Rutgers University and a B.S. in pharmacy from St. John’s University’s College of Pharmacy. He is a registered pharmacist in New Jersey and California.
TWST: What do you expect the sector to look like in five years?
Mr. Shenouda: We probably will have fewer large-cap names. I think we’ll probably see some acquisitions – I think Biogen Idec (BIIB) is on its way to being acquired at some point, with Carl Icahn involved in the name as well and having put themselves on the block about a year ago. That seems to be a foregone conclusion now. But the big question is at what price will it be acquired? Then we could see maybe one other name going. With one or two names going away, the sector becomes a few large caps with most companies in the mid- and small-cap categories. We’re also going to see more and more collaborations between biotech and pharma and/or large-cap biotech.
Biogen Idec Inc (BIIB) Has Potential to Generate $5 Billion with New MS Drug Tecfidera
March 14, 2014
Equinix (EQIX) CMO and WSJ “All-Star” Analyst Discuss Future of Volatile Data Storage Giant After Stock Plunges 30%
October 13, 2010
Lam Research (LRCX) and Teradyne (TER) Chosen as “Buy” Stocks by Deutsche Bank Senior Analyst for Value, Long-Term I
October 04, 2012
Biogen Inc (NASDAQ:BIIB) a High-Quality Company at a Bargain Price
November 07, 2016
“Great Companies” According to Great Companies
September 25, 2007
